Cytocristin 1mg Injection is a chemotherapy medication containing the active constituent Vincristine sulphate. This medication belongs to a class of drugs called vinca alkaloids, which inhibit the growth of cancer cells. It treats blood, head, breast, neck, kidney, bone, or lung cancers. It is used in treating rhabdomyosarcoma (cancer that affects muscle tissue) and neuroblastoma (cancer that develops from immature nerve cells). It may also be used to treat multiple myeloma (cancer of plasma cells), thyroid cancer, and a blood disorder known as idiopathic thrombocytopenic purpura (ITP). Cancer is a disorder in which cells multiply in an uncontrolled and abnormal manner.

This chemotherapy medicine should not be used if you have an untreated infection or Charcot-Marie-Tooth syndrome (a disorder that causes weakness in the leg muscles). Talk to your physician if you have breathing problems, mental health illness, liver disorders, low blood cell count, or nervous disorders, or if you are having radiotherapy before taking Cytocristin 1mg Injection. Like all chemotherapy drugs, it can cause side effects, such as nausea, vomiting, constipation, hair loss, and fatigue. Patients should discuss the potential benefits and risks of treatment with their doctor.

Cytocristin 1mg Injection used in the treatment of:

• Cancers of blood, head, neck, breast, kidney, bone, or lung
• Idiopathic thrombocytopenic purpura (ITP)
• Multiple myeloma
• Rhabdomyosarcoma
• Thyroid cancer
• Neuroblastoma

The therapeutic effect of Cytocristin 1mg Injection is to inhibit the growth and spread of cancer cells. It disrupts the formation and function of microtubules, which are structures inside cells that help with cell division and movement. By interfering with microtubule function, this medication can prevent cancer cells from dividing and multiplying and can also cause them to die.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Cytocristin 1mg Injection Injection and reduce effectiveness by causing undesirable side effects.

• Cytocristin 1mg Injection should be stored in a refrigerator between 2°C to 8°C.
• Protected from light.
• Keep it in its original packaging until it is ready to be used.
• Keep reach out of the reach of children and pets.
• Should be disposed of properly.

Cytocristin 1mg Injection is usually administered through intravenous injection (IV) by a healthcare professional in a hospital or clinical setting. It should not be taken orally or applied topically to the skin. If you miss a dose, then do not double the dose to make up for the missed one.

Like all medications, Cytocristin 1mg Injection Injection can cause side effects, although not everyone who takes it will experience them. 

Serious:

• Severe allergic reactions
• Pulmonary toxicity (lung damage)
• Liver toxicity
• Neurotoxicity (damage to the nervous system)
• Tumor lysis syndrome (life-threatening complication in which cancer cells release their contents into the bloodstream)

Common:

• Nausea and vomiting
• Constipation
• Loss of appetite
• Hair loss
• Fatigue
• Muscle weakness
• Numbness or tingling in the hands and feet (peripheral neuropathy)
• Increased risk of infection
• Easy bruising or bleeding
• Mouth sores
• Changes in mood or behavior
• Difficulty sleeping

If you are receiving Cytocristin 1mg Injection, it's important to be proactive in managing your treatment and monitoring your symptoms. Keep a close line of communication with your healthcare provider and report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Take steps to care for yourself physically and emotionally during treatment, and seek support from loved ones and professionals as needed. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. By being informed and engaged in your treatment, you can help ensure the best possible outcomes and manage any potential risks or complications.

1. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Cytotoxic agents, 12th edition, 2011, 1707.
2. KD Tripathi, Essentials of Medical Pharmacology, Anticancer drugs, 7th edition, 2013, 865.
3. Hospira UK Ltd, Electronic medicines compendium (emc), [Revised on March 2022] [ Accessed on 18 April 2023], https://www.medicines.org.uk/emc/files/pil.1501.pdf
4. Hospira, Inc, US Food and Drug Administration, [Revised on July 2013] [ Accessed on 18th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf
5. Jan Skubnik et al; Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics; Biology; Published on 31/08/2021; Accessed on 18th April 2023; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468923/